Article
First-in-class vs. Best-in-class: What Biotech Investors Need To Know
Ross McNaughton and Moira Sy examine the strategic calculus behind biotech investment decisions, analyzing whether venture capital and M&A activity gravitates toward pioneering first-in-class assets or optimized best-in-class therapies. The analysis explores how advances in AI, regulatory pathways, and market dynamics are reshaping risk profiles and determining which innovation strategies attract capital in today's selective funding environment.

Winston Taylor
